AST SpaceMobile, Inc. (ASTS), the company building a space-based cellular broadband network designed to connect directly to standard smartphones, saw its shares decline 2.60% on Tuesday to $35.93. The prior session's close stood at $36.89, marking a drop of roughly $0.96 per share. The decline was driven primarily by a third-quarter earnings report released after Monday's close that missed analyst estimates on both earnings and revenue, compounded by a price-target reduction from Bank of America Securities.
The most immediate catalyst behind the move was a quarterly report that underwhelmed. ASTS posted a net loss of $0.44 per share, wider than the roughly $0.40 loss analysts had forecast. Revenue reached $42.32 million — up about 187% year over year — but still came in below the consensus estimate of roughly $46 million, driven by gateway deliveries and U.S. government contract milestones rather than faster commercial-service ramp-up.
Notably, the company maintained its full-year 2026 revenue outlook of $150 million to $200 million and reiterated plans to begin intermittent nationwide coverage in key markets before the end of the year. Yet the top-line shortfall, coupled with rising operating expenses and a shifting satellite timeline, left investors questioning the pace of the company's commercial transition.
Adding pressure, Bank of America Securities lowered its price target on ASTS to $45 from $80 while maintaining a Neutral rating. The firm cited a slower launch cadence, later-than-expected commercial availability, and execution risk tied to the company's newly unveiled "Blacklift" reusable rocket initiative, which depends on engines supplied by Firefly Aerospace. The cautious note reinforced concerns that the path to continuous coverage and meaningful revenue remains contingent on milestones that have repeatedly slipped.
The decline in ASTS also reflected a wider risk-off tone across space and satellite names. Peer Rocket Lab slid after reporting its own third-quarter results, in which a wider loss overshadowed a record backlog. With launch capacity described by executives as "extremely constrained," investors weighed the shared execution and capital-intensity challenges facing the sector, contributing to a synchronized pullback.
The move came against a backdrop of heavy recent volatility in the name. Monday's session had delivered a sharp gain of roughly 14% following the announcement of a joint venture with Rakuten and approximately $1 billion in non-dilutive Japanese government funding. Tuesday's pullback represented a partial give-back of that rally as the market digested the earnings details and the analyst downgrade. Broader trading in the stock has been elevated relative to its typical daily average, consistent with a name moving on significant, competing headlines.
Investors are now focused on execution. The company targets approximately 45 BlueBird satellites in orbit by mid-2027 and has indicated launch agreements covering more than 100 satellites for deployment during 2027 and 2028. Key watch items include confirmation of launch dates for the next BlueBird batch, progress toward year-end intermittent service activation, and any updates on the government and commercial pipeline that management says could support upside to guidance. Risks remain substantial, including launch-vehicle availability, escalating capital expenditures, a growing debt load, and intensifying competition from direct-to-cell rivals.
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots, drawn from hundreds of available strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots varying by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see how algorithmic strategies are adapting to today's market environment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for ASTS moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 31 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +22.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTS advanced for three days, in 231 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
ASTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASTS as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for ASTS turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 47 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ASTS moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ASTS entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.117) is normal, around the industry mean (5.210). P/E Ratio (-15.037) is within average values for comparable stocks, (3.688). ASTS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.778). Dividend Yield (0.000) settles around the average of (0.067) among similar stocks. ASTS's P/S Ratio (147.059) is very high in comparison to the industry average of (11.937).
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ASTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a blank check company, which has formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry TelecommunicationsEquipment